Today: 13 June 2026
Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

New York, Feb 7, 2026, 15:24 EST — The market is now closed.

  • Goldman Sachs ended Friday’s session with a 4.3% gain.
  • The bank says it’s collaborating with AI upstart Anthropic, building out its own internal “AI agents.”
  • Midweek brings the delayed U.S. jobs and inflation figures, both with the potential to sway rate expectations.

Goldman Sachs finished Friday up 4.3% at $928.75, picking up momentum into the next U.S. session after buyers piled into some of the market’s bigger ticket stocks late in the week. Shares moved between $890.00 and $931.59, with volume at roughly 2.47 million.

Traders remain fixated on a potential AI shakeup brewing at the bank. Goldman is partnering with AI firm Anthropic, aiming to roll out “AI agents”—tools that can handle jobs like transaction accounting, onboarding, and due diligence, CNBC reported. The bank confirmed the details. Marco Argenti, Goldman’s CIO, told CNBC the software could “significantly reduce the time required to complete core operational processes,” but stopped short of offering a launch date. Reuters

So, here’s why this hits now: a mix of index mechanics and trading stances. Goldman played a key role in nudging the Dow over the 50,000-mark for the first time Friday, since the index gives more weight to higher-priced stocks. “What’s driven it recently has been the broadening that we have seen in the market,” said Chuck Carlson, chief executive at Horizon Investment Services. Reuters

The AI story isn’t exactly straightforward. According to Reuters, trading this week highlighted investors splitting the field into AI “enablers” and players exposed to risk, especially as costs and debt levels creep higher. “This divergence is not a vote against AI,” said Charu Chanana, chief investment strategist at Saxo, in a note. Reuters

The macro calendar is packed tighter than usual next week. Thanks to the federal government shutdown, economists at S&P Global Market Intelligence note that the January U.S. jobs report was pushed out—from Feb. 6 to Feb. 11—while the CPI inflation print will now land on Feb. 13. Payrolls are expected to add just 70,000; the unemployment rate, they’re saying, should stay put at 4.4%.

Fed signals aren’t turning bold yet, a point with real impact on banks’ rate-driven lines. Federal Reserve Vice Chair Philip Jefferson described himself as “cautiously optimistic” about the outlook on Friday, and said, “The current policy stance is well positioned to address the risks to both sides of our dual mandate.” He emphasized the need to let future decisions follow the data. Reuters

Goldman, on Feb. 6, put in a prospectus supplement for GS Finance Corp.’s “trigger autocallable” contingent yield notes maturing in 2029, tied to the Russell 2000 and S&P 500. These structured notes come with early redemption if certain index levels are hit. SEC

Still, the situation could easily flip. The bank isn’t giving a timeline for rolling out its AI agents, and the potential gains—quicker turns, cleaner data, leaner spending—are tough to quantify before launch. Any disappointment in the upcoming numbers or a surprise spike in inflation that jolts rate forecasts could sap risk appetite and put Friday’s rally to the test.

Right now, the calendar takes center stage as traders wait for fresh action. Markets open again Monday, offering that first look at follow-through. After that, all eyes shift to the delayed U.S. jobs numbers set for Feb. 11, with CPI following on Feb. 13. Both reports could shape expectations for rates—and for where Goldman’s stock heads next.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes
Previous Story

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Deutsche Telekom stock slips despite fresh buyback — what matters before earnings
Next Story

Deutsche Telekom stock slips despite fresh buyback — what matters before earnings

Go toTop